Compare

Ligand Pharmaceuticals/$LGND

1D1W1M3M6MYTD1Y5YMAX

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ticker
$LGND
Sector
Health
Primary listing
NASDAQ
Employees
47

LGND Metrics

BasicAdvanced
$6B
124.91
$2.39
1.01
-

What the Analysts think about LGND

Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.
Analyst projections of the future price of Ligand Pharmaceuticals stock.

Bulls say / Bears say

Royalty revenue rose 51% year on year to $70.3 million in the third quarter, and Ligand raised its full-year adjusted EPS outlook to $9.50–$9.75. That points to strong growth in its core royalty business. (Ligand Pharmaceuticals)
The XOMA acquisition added seven marketed products and 14 late-stage programmes, more than doubling Ligand’s portfolio to over 200 royalty assets. This broadens its sources of potential royalty income beyond its existing products. (Ligand Pharmaceuticals)
Palvella’s QTORIN rapamycin has received FDA priority review, with a decision due by 28 February 2027. If approved, Ligand is entitled to royalties of 8%–9.8%, offering a potential new source of growth. (The Motley Fool)
Ligand reported a $28.5 million net loss in the third quarter despite higher royalties, including a $35.7 million loss from changes in the fair value of investments. This shows reported earnings can be volatile even when operating royalties grow. (SEC)
Captisol sales fell to $7.9 million from $10.7 million in the third quarter, and were down year on year over the first nine months as well. Ligand says order timing affects these sales, making this revenue stream less predictable. (Ligand Pharmaceuticals)
Ligand’s partner Ovid said soticlestat narrowly missed the primary endpoint in a Phase 3 Dravet syndrome trial. The setback highlights that some pipeline assets may fail to deliver expected future milestones or royalties. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.

LGND Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

LGND Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.